Awaiting development: Guidance and quality standards

Showing 361 to 370 of 383

Guidance and quality standards awaiting development
Title	Type
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]	Technology appraisal guidance
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]	Technology appraisal guidance
Vamikibart for treating uveitic macular oedema [ID6671]	Technology appraisal guidance
Veligrotug for treating thyroid eye disease [ID6636]	Technology appraisal guidance
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]	Technology appraisal guidance
VER-01 for treating chronic low back pain [ID6638]	Technology appraisal guidance
Vilobelimab for treating COVID 19 [TSID11815]	Technology appraisal guidance
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [ID6736]	Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]	Technology appraisal guidance
Vulnerable populations: strategies for tackling inequalities	Quality standard